SIHUAN PHARM(00460),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00460 SIHUAN PHARM

Market Closed 04-02 16:08:21

1.410

-0.040

-2.76%

High1.470	Low1.390	Vol29.70M
Open1.460	D1 Closing1.450	Amplitude5.52%
Mkt Cap12.90B	Tradable Cap12.90B	Total Shares9.15B
T/O42.21M	T/O Rate0.32%	Tradable Shares9.15B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"SIHUAN PHARM","latestPrice":1.41,"timestamp":1775117301002,"preClose":1.45,"halted":0,"volume":29700000,"delay":0,"changeRate":-0.027586206896551748,"floatShares":9146000000,"shares":9146000000,"eps":0.022409467975044672,"marketStatus":"Market Closed","change":-0.04,"latestTime":"04-02 16:08:21","open":1.46,"high":1.47,"low":1.39,"amount":42208820,"amplitude":0.055172,"askPrice":1.41,"askSize":324000,"bidPrice":1.4,"bidSize":957000,"shortable":3,"etf":0,"ttmEps":0.022409467975044672,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1288195200000,"exchange":"SEHK","adjPreClose":1.45,"dividendRate":0.007976,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.7046634518127748,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460","defaultTab":"news","newsList":[{"id":"1141444588","title":"Biocytogen-B Shares Extend Rally with Over 6% Gain on AI-Driven Obesity Drug Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=1141444588","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141444588?lang=en_us&edition=fundamental","pubTime":"2026-04-02 11:36","pubTimestamp":1775100980,"startTime":"0","endTime":"0","summary":"Biocytogen-B (02315) rose more than 6% again, reaching HK$63.3 at the time of writing, with a trading volume of HK$56.0117 million. The increase follows the announcement of a formal strategic...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","06978","AGIX","BK1191","BK4585","02315","AIPO","CHAT","BK1515","BK0216","BK4588","VXUS","159992","688796","BK1574","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158222835","title":"Hong Kong Stock Announcement Highlights | Biocytogen-B and Sihuan Pharmaceutical Form Strategic Partnership to Accelerate Innovative Drug Development in Weight Loss and Other Areas","url":"https://stock-news.laohu8.com/highlight/detail?id=1158222835","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158222835?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:21","pubTimestamp":1775092887,"startTime":"0","endTime":"0","summary":"Major Developments: Biocytogen-B (02315) and Sihuan Pharmaceutical (00460) have entered into a strategic collaboration to accelerate the research and development of innovative drugs in multiple...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","LU1719994722.HKD","LU0211977185.USD","LU0819121731.USD","LU0084288322.USD","LU0289961442.SGD","LU0359201885.HKD","LU0449509016.USD","HYDD.SI","LU0315178854.USD","SG9999002828.SGD","LU0511384066.AUD","LU1242518857.USD","LU0588545904.SGD","BK1594","LU2097828805.USD","LU1770034418.SGD","LU0293314216.USD","SG9999014674.SGD","SG9999015986.USD","LU0039217434.USD","BK1540","BK1600","LU1961090484.USD","BK4588","EVS.SI","LU0359201612.USD","LU0052750758.USD","LU0561508036.HKD","LU0348827113.USD","81211","LU0348825331.USD","LU0348805143.USD","LU1188198961.HKD","IE00BZ08YR35.GBP","LU0244354667.USD","LU0823426480.USD","LU1813983027.USD","LU1868837565.USD","LU1868838027.USD","LU0359202008.SGD","LU0314109678.HKD","IE00BD6J9T35.USD","LU0823038988.USD","LU0417516902.SGD","LU1303224171.USD","00460","BK1574","BK1240","LU0327786744.USD","LU2348774022.SGD","BK1515","LU0229945570.USD","688796","LU0143863784.USD","LU0165289439.USD","LU1794554557.SGD","LU0417516738.SGD","SG9999015978.USD","LU0463099449.HKD","LU0828238088.HKD","02315","BK1582","LU2778985437.USD","BK4585","LU0348735423.USD","LU1328277881.USD","LU0175139822.USD","IE00BZ08YS42.EUR","LU0871576103.HKD","LU2097828557.USD","LU0469268626.HKD","LU0315179316.USD","LU0593848301.USD","LU0307460666.USD","002594","LU0516422366.SGD","LU0054450605.USD","LU1282651121.HKD","LU2249611893.SGD","BK1593","LU1282651048.USD","SG9999015945.SGD","LU1868837722.USD","LU0143863198.USD","LU0708995583.HKD","BK1589","LU2449936058.SGD","LU0289960550.SGD","LU2097828631.EUR","LU0043850808.USD","SG9999015952.SGD","LU0164865239.USD","IE00B0JY6N72.USD","LU1861214812.USD","BK1521","LU0320764599.SGD","LU0516422952.EUR","LU2153592121.USD","LU0572944931.SGD","LU0594300179.USD","LU0543330566.HKD","LU0823414551.USD","LU0269904917.USD","BYDDY","LU1808992512.USD","LU0856984785.SGD","SG9999006514.SGD","BK1522","LU1242518931.SGD","GELYY","LU0516423091.SGD","LU0254981946.USD","LU0823414478.USD","LU0531970944.HKD","LU0605514214.HKD","LU1720050803.USD","LU1224444064.USD","BK0216","LU1251922891.USD","LU0594300419.USD","LU0540923850.HKD","LU0588545730.USD","LU0509642566.USD","SG9999006597.SGD","LU1880383366.USD","BK1119","LU2506951792.HKD","LU0505663152.USD","LU0164872284.USD","LU2360107325.USD","LU0823426308.USD","LU0531971595.HKD","LU1880383440.USD","LU0449515922.USD","LU2294711713.HKD","LU2476274720.SGD","LU0259732245.USD","LU0289739343.SGD","LU0823039010.USD","LU0214875030.USD","LU2097828714.EUR","LU2039709279.SGD","LU0819123356.HKD","BK1191","BK1610","LU0634319403.HKD","LU1861219969.SGD","BK1509","LU0979878070.USD","SG9999002463.SGD","LU2357125470.USD","LU0588545490.SGD","LU0650527681.SGD","LU0516422440.USD","LU1023057109.AUD","BK1161","BK1539","SG9999001226.SGD","LU0588546209.SGD","BK1124","LU2097828474.EUR","80175","LU2476274308.USD","LU2399975544.HKD","LU0865486749.SGD","IE00BZ08YT58.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122797956","title":"IEA Warns of Doubling Oil Supply Gap in April; US Launches Manned Moon Mission Rocket","url":"https://stock-news.laohu8.com/highlight/detail?id=1122797956","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122797956?lang=en_us&edition=fundamental","pubTime":"2026-04-02 07:43","pubTimestamp":1775087031,"startTime":"0","endTime":"0","summary":"The head of the International Energy Agency (IEA) stated that the oil supply gap in April will double compared to March. Fatih Birol, the IEA chief, mentioned in a podcast released on Wednesday that...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759","BK4585","BK1141","BK1610","BK1515","LU0067412154.USD","LU1008478684.HKD","06681","BK4588","LU1152091754.HKD","BK1194","300750","02315","300759","LU1152091168.USD","03750","02256","BK1600","BK1116","LU1993786604.SGD","BK4570","LU1960683339.HKD","XLE","BK1576","LU1807302812.USD","00460","01857","BK1191","BK1593","BK1161","688796","LU0880133367.SGD","XOP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624525984","title":"Asian Penny Stocks Under US$10B Market Cap: 3 Picks To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2624525984","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624525984?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:02","pubTimestamp":1775080964,"startTime":"0","endTime":"0","summary":"Amidst global market volatility driven by geopolitical tensions and fluctuating energy prices, Asian markets have been navigating a complex landscape. This environment has prompted investors to look beyond traditional large-cap stocks, turning their attention to opportunities in smaller or newer companies often categorized as penny stocks. Though the term 'penny stock' may seem outdated, it remains relevant for those seeking potential growth in companies with solid financial foundations...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3071000-choice2-main-header/1585186751359","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3071000-choice2-main-header/1585186751359"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/sg/capital-goods/sgx-bs6/yangzijiang-shipbuilding-holdings-shares/news/asian-penny-stocks-under-us10b-market-cap-3-picks-to-conside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/sg/capital-goods/sgx-bs6/yangzijiang-shipbuilding-holdings-shares/news/asian-penny-stocks-under-us10b-market-cap-3-picks-to-conside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0516422952.EUR","BK6057","LU0516423091.SGD","LU1242518857.USD","00460","LU0516422440.USD","SG9999013460.SGD","BK6065","SG9999014484.SGD","LU0082770016.USD","SG9999013486.USD","SG9999014492.USD","SGXZ58947870.SGD","BK1109","00020","LU0082770016.SGD","BS6.SI","SGXZ27511609.SGD","BK1615","LU0979878070.USD","LU0164939612.USD","LU0620787316.HKD","SG9999003826.SGD","SGXZ24219693.SGD","BK6504","80020","LU0516422366.SGD","LU0516423174.USD","BK1613","SG9999016042.SGD","BK8040","SG9999004360.SGD","SG9999000475.SGD","SGXZ43160589.SGD","BK6081","SG9999000343.SGD","LU1242518931.SGD","SG9999002679.SGD","BK6515","SG9999013478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624519568","title":"Assessing Sihuan Pharmaceutical Holdings Group’s Valuation After Earnings Turnaround And Positive Bireociclib Phase 3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2624519568","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624519568?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:30","pubTimestamp":1775046635,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group (SEHK:460) has drawn investor attention after reporting full year 2025 earnings, showing CNY 2,618.01 million in sales and CNY 179.7 million in net income, alongside positive final Phase 3 data for Bireociclib.\nSee our latest analysis for Sihuan Pharmaceutical Holdings Group.\nThe earnings turnaround and Bireociclib news sit alongside a 17.9% 90 day share price return and a 121.2% 1 year total shareholder return. However, the 5 year total shareholder return...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/assessing-sihuan-pharmaceutical-holdings-groups-valuation-af-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/assessing-sihuan-pharmaceutical-holdings-groups-valuation-af-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1593","00460","BK1515","BK1191","BK1600","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624597384","title":"BRIEF-Sihuan Pharma Signs Strategic Collaboration With Biocytogen For AI-Driven Drug R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2624597384","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624597384?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:53","pubTimestamp":1775040780,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Signs Strategic Collaboration With Biocytogen For AI-Driven Drug R&DApril 1  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:SIGNS STRATEGIC COLLABORATION WITH BIOCYTOGEN FOR AI-DRIVEN DRUG R&DFIRST PROJECT FOCUSES ON NEXT-GENERATION WEIGHT LOSS DRUGFurther company coverage: 0460.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0HF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1593","BK0216","BK1600","688796","00460","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143375483","title":"SIHUAN PHARM and BIOCYTOGEN-B Forge Strategic Alliance to Accelerate Innovative Drug Development in Weight Loss and Other Areas Using AI-Powered Human Antibody Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1143375483","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143375483?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:12","pubTimestamp":1775034756,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) has announced that the Group has officially entered into a strategic collaboration agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 688796.SH;...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1600","02315","AIPO","688796","00460","06978","BK1161","CHAT","BK0216","BK1593","AGIX","BK1191","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146966129","title":"Sihuan Pharm partners with Biocytogen to accelerate AI-driven fully human antibody R&D for next-gen weight-loss therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1146966129","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146966129?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:07","pubTimestamp":1775034439,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharm) has signed a strategic collaboration agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. The partnership combines Sihuan Pharm’s...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624961275","title":"Sihuan Pharma signs strategic R&D collaboration with Biocytogen on AI antibody platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2624961275","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624961275?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:02","pubTimestamp":1775034170,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical signed a strategic collaboration agreement with Biocytogen to jointly develop innovative drugs, including a weight-loss program, using an AI-driven fully human antibody discovery platform.First project targets a next-generation obesity candidate aimed at boosting energy expenditure while preserving or increasing muscle mass.Biocytogen will provide technical support through its target-humanized mouse models, in vivo efficacy platforms, fully human antibody discovery tools, and AI-enabled R&D systems.Sihuan will contribute drug development, large-scale manufacturing, and global commercialization capabilities to advance R&D and rollout of resulting products.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL60qPT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B19Z6F94.USD","TECH","BK1593","BK1191","LU2237957811.SGD","BK1600","BK1515","00460","LU2237957902.USD","BK4121","IE00B64QTZ34.USD","IE0034390439.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624961915","title":"Sihuan Pharma - First Project Focuses on Next-Generation Weight Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2624961915","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624961915?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:01","pubTimestamp":1775034085,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0HF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","BK1600","BK1515","BK1191","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166458779","title":"Sihuan Pharma: March 2026 Share Capital Stable, No New Issuances or Treasury Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1166458779","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166458779?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:25","pubTimestamp":1775031904,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharma) reported that its share capital structure remained unchanged in March 2026. The company’s authorised share capital stood at HKD 1.00 billion,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175835368","title":"Sihuan Pharmaceutical Declares RMB 0.0096 Final Dividend for FY 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1175835368","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175835368?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:24","pubTimestamp":1774931057,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. announced a final ordinary cash dividend of RMB 0.0096 per share for the financial year ended 31 December 2025. Using the declared exchange rate of RMB 1 :...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129525813","title":"Sihuan Pharmaceutical Returns to Profitability with FY Net Income of 180 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1129525813","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129525813?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:18","pubTimestamp":1774930711,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical (00460) announced its annual results for the period ended December 31, 2025. Total revenue reached approximately RMB 2.618 billion, representing an increase of about 37.7%...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1515","BK1191","BK1600","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188285155","title":"Sihuan Pharmaceutical 2025 Results: Revenue Climbs 37.7%, Turns Profitable on Medical Aesthetics Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1188285155","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188285155?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:04","pubTimestamp":1774929877,"startTime":"0","endTime":"0","summary":"Hong Kong-listed Sihuan Pharmaceutical reported FY2025 revenue of RMB2.62 billion, up 37.7% year-on-year, driven mainly by a near-doubling of medical aesthetics sales to RMB1.49 billion. Gross profit...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623437405","title":"Sihuan Pharma FY25 revenue climbs 37.7% to RMB 2.6 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2623437405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623437405?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:01","pubTimestamp":1774929698,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical swung to profit of RMB 185 million for 2025, reversing a loss a year earlier.Revenue climbed 37.7% to RMB 2.6 billion, driven primarily by medical aesthetics.Operating profit rose to RMB 607 million, helped by higher medical aesthetics sales, tighter cost control, and improved innovative drug revenue.Board proposed a final cash dividend of RMB 0.96 cents per share; cash and equivalents, wealth management products, pledged deposits, and time deposits totaled RMB 4.4 billion at year-end.Group guided 2026 as the first year of a new three-year plan, targeting deeper domestic penetration and faster overseas expansion in medical aesthetics while accelerating innovative drug commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL6CDSrG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1515","BK1593","BK1191","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623051374","title":"Sihuan Pharma -  FY Profit Attributable RMB179.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623051374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623051374?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:01","pubTimestamp":1774929694,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40I1AP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1515","BK1593","00460","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623034374","title":"Sihuan Pharma -  Final Cash Dividend of RMB0.96 Cents per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2623034374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623034374?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:01","pubTimestamp":1774929662,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLXC00322:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1600","BK1593","BK1515","BK1191","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315221","title":"Xuanzhu Biopharma FY25 loss narrows 55.9% to RMB 250 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315221","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315221?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:58","pubTimestamp":1774864687,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical posted a net loss of RMB 250 million, narrowing 55.9%.Operating expenses fell 56.6% to RMB 250 million.Commercial rollout accelerated with two oncology launches in 2025, while cash and cash equivalents climbed to RMB 650 million following the October IPO.For 2026, focus remains on expanding NRDL access, advancing indication expansions and pipeline development, while tightening cost management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL414TVf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1593","BK1600","00460","BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621306116","title":"Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2621306116","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621306116?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:48","pubTimestamp":1774352903,"startTime":"0","endTime":"0","summary":"Sihuan said its majority-owned unit Xuanzhu Biopharma published final Phase 3 BRIGHT-2 results for CDK2/4/6 inhibitor piruoxib in combination with fulvestrant in JAMA Oncology.The company stated the study reported a median progression-free survival of 14.7 months versus 7.3 months, with a 46% reduction in risk of disease progression or death.Sihuan said the treatment achieved an objective response rate of 50.3% versus 16.7% in patients with measurable disease.The company said the drug has received China approvals for use in HR+/HER2- advanced or metastatic breast cancer in combination with fulvestrant, as monotherapy, and in combination with an aromatase inhibitor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Ho","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL3kmNYg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1515","00460","BK1191","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069888","title":"Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069888","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069888?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:06","pubTimestamp":1774350387,"startTime":"0","endTime":"0","summary":"Xuanzhu reported final Phase 3 BRIGHT-2 results for its breast cancer product bireociclib in combination with fulvestrant, with the analysis published in JAMA Oncology.The company said median progression-free survival was 14.7 months versus 7.3 months for placebo plus fulvestrant, with a 46% reduction in risk of progression or death .In patients with measurable disease, the objective response rate was 50.3% versus 16.7% for the control group.Xuanzhu said bireociclib has been approved in China for use with fulvestrant in HR+/HER2- advanced or metastatic breast cancer after progression on prior endocrine therapy, positioning it for broader clinical adoption.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL20tgp6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1191","02575","00460","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":0.1016},{"period":"1month","weight":0.0071},{"period":"3month","weight":0.1016},{"period":"6month","weight":-0.2123},{"period":"1year","weight":1.1527},{"period":"ytd","weight":0.1463}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of pharmaceutical products and aesthetic products. The Company operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.119825},{"month":2,"riseRate":0.5,"avgChangeRate":0.000395},{"month":3,"riseRate":0.3125,"avgChangeRate":-0.03194},{"month":4,"riseRate":0.6,"avgChangeRate":0.045408},{"month":5,"riseRate":0.428571,"avgChangeRate":0.020898},{"month":6,"riseRate":0.571429,"avgChangeRate":0.003131},{"month":7,"riseRate":0.571429,"avgChangeRate":0.007501},{"month":8,"riseRate":0.5,"avgChangeRate":-0.014353},{"month":9,"riseRate":0.214286,"avgChangeRate":-0.045133},{"month":10,"riseRate":0.571429,"avgChangeRate":0.029461},{"month":11,"riseRate":0.466667,"avgChangeRate":0.008386},{"month":12,"riseRate":0.4,"avgChangeRate":-0.017588}],"exchange":"SEHK","name":"SIHUAN PHARM","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SIHUAN PHARM(00460),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SIHUAN PHARM(00460) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SIHUAN PHARM,00460,SIHUAN PHARM股票,SIHUAN PHARM股票老虎,SIHUAN PHARM股票老虎国际,SIHUAN PHARM行情,SIHUAN PHARM股票行情,SIHUAN PHARM股价,SIHUAN PHARM股市,SIHUAN PHARM股票价格,SIHUAN PHARM股票交易,SIHUAN PHARM股票购买,SIHUAN PHARM股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SIHUAN PHARM(00460),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SIHUAN PHARM(00460) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}